NASDAQ:TPST

Tempest Therapeutics (TPST) Stock Forecast, Price & News

$1.45

+0.01 (+0.69%)

(As of 06/2/2023 ET)

Compare

Today's Range: $1.42
▼
$1.51
50-Day Range: $1.37
▼
$3.76
52-Week Range: $1.06
▼
$4.21

Volume: 82,278 shs
Average Volume: 69,563 shs
Market Capitalization: $16.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Tempest Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,164.4% Upside
$18.33 Price Target
Short Interest: Healthy
1.52% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.36
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.19) to ($2.20) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

Medical Sector

798th out of 983 stocks

Pharmaceutical Preparations Industry

400th out of 486 stocks

3.5

Analyst's Opinion

Consensus Rating
Tempest Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.33, Tempest Therapeutics has a forecasted upside of 1,164.4% from its current price of $1.45.
Amount of Analyst Coverage
Tempest Therapeutics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.52% of the float of Tempest Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Tempest Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Tempest Therapeutics has recently increased by 144.20%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Tempest Therapeutics does not currently pay a dividend.
Dividend Growth
Tempest Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TPST.

1.9

News and Social Media Coverage

News Sentiment
Tempest Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Tempest Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for TPST on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tempest Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.14% of the stock of Tempest Therapeutics is held by insiders.
Percentage Held by Institutions
Only 29.32% of the stock of Tempest Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Tempest Therapeutics are expected to decrease in the coming year, from ($2.19) to ($2.20) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tempest Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tempest Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tempest Therapeutics has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Tempest Therapeutics (NASDAQ:TPST) Stock

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development and discovery of small molecule drugs for the treatment of cancer. The company was founded in 2011 and is headquartered in Brisbane, CA.

Receive TPST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tempest Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TPST Stock News Headlines

May 31, 2023 | finance.yahoo.com

Tempest to Present at the Jefferies Global Healthcare Conference

May 30, 2023 | markets.businessinsider.com

Analyst Ratings for Tempest Therapeutics

June 4, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

May 25, 2023 | finance.yahoo.com

Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

May 25, 2023 | finance.yahoo.com

Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

May 19, 2023 | finance.yahoo.com

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 17, 2023 | americanbankingnews.com

Tempest Therapeutics, Inc. Forecasted to Earn Q2 2023 Earnings of ($0.64) Per Share (NASDAQ:TPST)

May 16, 2023 | americanbankingnews.com

Tempest Therapeutics, Inc. to Post Q2 2023 Earnings of ($0.52) Per Share, William Blair Forecasts (NASDAQ:TPST)

June 4, 2023 | Behind the Markets (Ad)

⚡ 2,467% Return on Israeli Laser Company?

This advanced laser system is active in 80 countries around the world. And at the center of this massive market is a small firm in Israel. Our research shows that anyone who gets in today could see a return of 2,467%. But that's only if the company doesn't get taken over for a fast 300% gain first.

May 12, 2023 | msn.com

HC Wainwright & Co. Reiterates Tempest Therapeutics (TPST) Buy Recommendation

May 11, 2023 | finanznachrichten.de

Tempest Therapeutics: Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Tempest Therapeutics (TPST), MannKind (MNKD) and Alkermes (ALKS)

May 10, 2023 | finance.yahoo.com

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

May 10, 2023 | finance.yahoo.com

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

May 1, 2023 | msn.com

Tempest Therapeutics, Inc. (TPST) Upgraded to Buy: What Does It Mean for the Stock?

May 1, 2023 | americanbankingnews.com

Tempest Therapeutics (NASDAQ:TPST) Price Target Raised to $14.00

April 29, 2023 | marketwatch.com

8-K: Tempest Therapeutics, Inc.

April 29, 2023 | msn.com

Ladenburg Thalmann Maintains Tempest Therapeutics (TPST) Buy Recommendation

April 29, 2023 | americanbankingnews.com

Short Interest in Tempest Therapeutics, Inc. (NASDAQ:TPST) Declines By 29.9%

April 28, 2023 | markets.businessinsider.com

Tempest Announces Positive Results From Phase 1b/2 Trial Of TPST-1120 In Hepatocellular Cancer

April 28, 2023 | msn.com

Tempest Soars after Positive Clinical Data for TPST-1120

April 28, 2023 | msn.com

Tempest surges ~40% as TPST-1120 shows promise in liver cancer trial

April 28, 2023 | finance.yahoo.com

Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

April 27, 2023 | finance.yahoo.com

Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

April 26, 2023 | benzinga.com

Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting

April 26, 2023 | finance.yahoo.com

Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting

April 17, 2023 | finance.yahoo.com

Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting

See More Headlines

TPST Price History

30 days | 90 days | 365 days | Advanced Chart

TPST Company Calendar

Last Earnings: 3/22/2023
Today: 6/04/2023
Next Earnings (Estimated): 8/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TPST
CUSIP: N/A
CIK: 1544227
Web: www.millendo.com
Phone: 415-798-8589
Fax: N/A
Employees: 14
Year Founded: 2012

Price Target and Rating

Average Stock Price Forecast: $18.33
High Stock Price Forecast: $35.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +589.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.63)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-35,710,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -153.57%
Return on Assets: -63.97%

Debt

Debt-to-Equity Ratio: 0.81
Current Ratio: 3.28
Quick Ratio: 3.28

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.95 per share
Price / Book: 1.53

Miscellaneous

Outstanding Shares: 11,586,000
Free Float: 10,990,000
Market Cap: $16.80 million
Optionable: Not Optionable
Beta: 0.91

Social Links

Key Executives

Stephen R. Brady
Chief Executive Officer & Director

Thomas W. Dubensky
President & Director

Nicholas Maestas
Secretary, Vice President-Finance & Strategy

Sam Whiting
Chief Medical Officer & Executive Vice President

Darrin Bomba
Vice President-Clinical Operations

Key Competitors

View All Competitors

Institutional Ownership

Susquehanna International Group LLP
Bought 11,087 shares on 5/16/2023
Ownership: 0.096%

View All Institutional Transactions

TPST Stock - Frequently Asked Questions

Should I buy or sell Tempest Therapeutics stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tempest Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TPST shares.
View TPST analyst ratings or view top-rated stocks.
What is Tempest Therapeutics' stock price forecast for 2023?: 4 analysts have issued 1-year target prices for Tempest Therapeutics' stock. Their TPST share price forecasts range from $6.00 to $35.00. On average, they anticipate the company's share price to reach $18.33 in the next twelve months. This suggests a possible upside of 1,164.4% from the stock's current price.
View analysts price targets for TPST or view top-rated stocks among Wall Street analysts.
How have TPST shares performed in 2023?: Tempest Therapeutics' stock was trading at $1.15 on January 1st, 2023. Since then, TPST shares have increased by 26.1% and is now trading at $1.45.
View the best growth stocks for 2023 here.
Are investors shorting Tempest Therapeutics?: Tempest Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 77,900 shares, an increase of 144.2% from the April 30th total of 31,900 shares. Based on an average daily trading volume, of 238,100 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.5% of the company's stock are short sold.
View Tempest Therapeutics' Short Interest.
When is Tempest Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our TPST earnings forecast.
How were Tempest Therapeutics' earnings last quarter?: Tempest Therapeutics, Inc. (NASDAQ:TPST) released its earnings results on Wednesday, March, 22nd. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.09.

When did Tempest Therapeutics' stock split?: Tempest Therapeutics shares reverse split before market open on Friday, June 25th 2021. The 1-15 reverse split was announced on Friday, June 25th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 28th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What is Tempest Therapeutics' stock symbol?: Tempest Therapeutics trades on the NASDAQ under the ticker symbol "TPST."
Who are Tempest Therapeutics' major shareholders?: Tempest Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Susquehanna International Group LLP (0.10%). Insiders that own company stock include Thomas W Dubensky and Thomas Woiwode.
View institutional ownership trends.
How do I buy shares of Tempest Therapeutics?: Shares of TPST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Tempest Therapeutics' stock price today?: One share of TPST stock can currently be purchased for approximately $1.45.
How much money does Tempest Therapeutics make?: Tempest Therapeutics (NASDAQ:TPST) has a market capitalization of $16.80 million. The company earns $-35,710,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis.
How can I contact Tempest Therapeutics?: Tempest Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The official website for the company is www.millendo.com. The company can be reached via phone at 415-798-8589 or via email at stephanie@sternir.com.

This page (NASDAQ:TPST) was last updated on 6/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial